Press Release: Avaxia Biologics : New Study: Avaxia Biologics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

(PR-inside.com) Summary Avaxia Biologics, Inc. (Avaxia) is a clinical-stage biotechnology company which offers gut-targeted antibody therapeutics for gastroenterology diseases. The company develops and markets drugs for orphan diseases and pediatric indications. Avaxia provides its proprietary technology platform to develop gut-targeted antibody therapeutics. It offers AVX-470, an oral anti-TNF antibody for inflammatory bowel disease. Its AVX-470 has completed a phase 1b clinical trial in active ulcerative colitis patients. The company partners with Biomedical Advanced Research and Development Authority for the research and development of an oral antibody therapy. Avaxia is headquartered in Lexington, Massachusetts, the US. Full Report Details at - http://www.fastmr.com/prod/990393_avaxia_biologics.aspx?afid=701 Avaxia Biologics, Inc. ..